Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: BIOA

BioAge Labs, Inc.

Healthcare | Biotechnology

No licensed closing price on file for BIOA. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-2.38

BioAge Labs, Inc. (NASDAQ: BIOA) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 20:36 UTC.

What BioAge Labs, Inc. does

BioAge is a clinical-stage biopharmaceutical company developing drug candidates to treat metabolic diseases by studying how aging affects human biology. The company's lead program, BGE-102, is an orally available small-molecule NLRP3 inhibitor being tested for cardiometabolic disease and diabetic macular edema, with early clinical data showing potential to reduce inflammation markers and improve retinal health. BGE-102 uses a distinct mechanism with patent protection for its unique binding site.

Summarized from BioAge Labs, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-2.38
Debt/equity0.01

Charts

Charts are in the appInteractive charts for BIOA are available in Oxford Ledge.
Open BIOA in Oxford Ledge →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-07-01
Most recent filed transactions — July 2026:
  • 2026-07-01Principal Accounting OfficerOption exercise14,198$62.2K
  • 2026-07-01Principal Accounting OfficerOption exercise9,301$100.9K
  • 2026-07-01Principal Accounting OfficerStock Option (Right to Buy)Option exercise-4,290—
Sign in to see all transactions →

Company news

View all →

Questions this page answers

What does BioAge Labs, Inc. do?

BioAge is a clinical-stage biopharmaceutical company developing drug candidates to treat metabolic diseases by studying how aging affects human biology.

When did BIOA last file with the SEC?

BioAge Labs, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-12. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 20:36 UTC. This page is also available as JSON at /api/data?ticker=BIOA and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for BIOA and 5,000+ tickers.

Create a free account — keep BIOA
For your agent
GET /api/data?ticker=BIOA

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt